KSQ Therapeutics Taps Blueprint’s Wolf for Chief Medical Officer

KSQ Therapeutics has appointed Beni Wolf to serve as chief medical officer. Wolf joins Cambridge, MA-based KSQ from Blueprint Medicines, where he was senior vice president, clinical development. His experience also includes posts at Merrimack Pharmaceuticals (NASDAQ: [[ticker:MACK]]), ImmunoGen (NASDAQ: [[ticker:IMGN]]), Amgen (NASDAQ: [[ticker:AMGN]]), and Genentech.

Cambridge, MA-based KSQ also named Douglas Pagán chief financial officer. Pagán joins KSQ from Paratek Pharmaceuticals. John Trzupek, KSQ’s head of corporate of corporate development and interim CFO, was promoted to chief business officer. KSQ is using the CRISPR gene-editing technology to develop new treatments for cancer.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan